Farxiga's march to become mega-blockbuster goes on

2 October 2020

AstraZeneca’s (LSE: AZN) Farxiga (dapagliflozin) is already a blockbuster, boasting 2019 sales of $1.47 billion based on an initial approval as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes (T2D) and to reduce the risk of hospitalization for heart failure (hHF) in patients with T2D and established cardiovascular (CV) disease or multiple CV risk factors.

But its star is set to rise further. The drug won a second US approval in May to reduce the risk of CV death and hHF in adults with heart failure (HF) with reduced ejection fraction, with and without T2D, and now it is closing in on a third approval.

Farxiga, which is branded as Forxiga in Europe, has been granted Breakthrough Therapy Designation (BTD) in the USA for patients with chronic kidney disease (CKD), with and without T2D.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK